| Document |
Document Title |
|
JP4976134B2 |
Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ ...
|
|
JP2012121887A |
To provide a compound particularly useful for the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder hypersensitivity and urinary incontinence.A compound having a formula (I) or a pharmaceutically acc...
|
|
JP2012514655A |
Fluorinated compounds and methods of making fluorinated compounds are described herein.
|
|
JP4960254B2 |
Compounds having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R1, R2 and R3 are as defined herein. These compounds are particularly useful in the treatment of pain, inflammato...
|
|
JP4954895B2 |
The invention is concerned with novel heteroarylacetamides of formula (I) Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb) (I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptabl...
|
|
JP2012513469A |
The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complicati...
|
|
JP2012513420A |
The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, to methods of preparing such derivatives, to compositions comprising them and therapeutic use thereof.
|
|
JP2012107008A |
To provide a novel compound which has a β2 adrenaline receptor agonist activity and a muscarine receptor antagonist activity.The quaternary ammonium salt compound shown by formula (I) or its salt which is pharmacologically accepted has ...
|
|
JP2012107001A |
To provide a therapeutic agent for diseases induced by the production, secretion or deposition of amyloid β protein.An amyloid β production inhibition drug composition contains a compound of formula (I), a pharmaceutically acceptable s...
|
|
JP4948677B2 |
TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS Compounds of formula I wherein: R 1 is and R 2 , R 4 , and R 6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mT...
|
|
JP4944012B2 |
The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5...
|
|
JP2012509354A |
The present invention relates to novel 8-azabicyclo[3.2.1]oct-2-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and t...
|
|
JP4918477B2 |
A 1-amino-phthalazine derivative of general formula (I) wherein the substituents are as defined herein. Also disclosed are a method for preparing such compounds, intermediates for use in such method and medical treatments using the compo...
|
|
JP2012072145A |
To provide a novel VR1 antagonist useful for treatment of pain, inflammatory thermalgesia, urorrhea and bladder hyperactivity.The compound is represented by formula (I) (wherein X1 to X5 are each a nitrogen atom or the like; R8a, R8b and...
|
|
JP2012067135A |
To provide a technetium or rhenium radio-labelled dopamine transporter (DAT) imaging agent which is capable of crossing the blood brain barrier and has a high binding affinity and selectivity for the DAT.A tropane compound is linked thro...
|
|
JP2012507483A |
Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, p...
|
|
JP2012505898A |
The present invention relates to novel Pyrrolidine, Piperidine and Piperazine Derivatives, pharmaceutical compositions comprising the Pyrrolidine, Piperidine and Piperazine Derivatives and the use of these compounds for treating or preve...
|
|
JP4889920B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP4871290B2 |
Agents for pest control comprising cyclic amine compounds represented by the formula (1) or salts thereof or N-oxides thereof as an active ingredient, wherein Cy 1 represents an unsubstituted or substituted 5-membered heterocycle or unsu...
|
|
JP4871866B2 |
The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected fro...
|
|
JP2012502051A |
The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutic...
|
|
JP4854970B2 |
The present invention provides compounds of the formula: wherein R 1 is C 3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C 1-6 alkyl optionally substituted by one or more fluorine atoms, or C 3-6 cycloalkylmethyl...
|
|
JP4853965B2 |
The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their prep...
|
|
JP4846592B2 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
JP2011256200A |
To provide a compound suitable for emergent measures and precaution for headache especially migraine, cluster headache and tension headache.There are provided compounds of general formula (I) selected from compounds (386)-(557), their ta...
|
|
JP4834837B2 |
A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.
|
|
JP2011241227A |
To provide novel compounds, which act as ligands for nicotinic acetylcholine receptors (nACh receptors).The present invention relates generally to the field of ligands for the nicotinic acetylcholine receptors (nACh receptors), activatio...
|
|
JP4825792B2 |
This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.
|
|
JP4815083B2 |
In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring th...
|
|
JP4810423B2 |
The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various...
|
|
JP4809229B2 |
An organic oxidation catalyst for alcohols which is environmentally less harmful and with which efficient oxidation can be conducted. The oxidation catalyst for alcohols is a 1-alkyl-2-azadamantan-N-oxyl which has a nitroxyl group incorp...
|
|
JP2011219382A |
To provide a method for manufacturing an N-oxyl compound, which can manufacture a high-purity N-oxyl compound with high yield.When the N-oxyl compound is manufactured by reacting a secondary amine with hydrogen peroxide, the N-oxyl compo...
|
|
JP4804346B2 |
A chemical compound represented by the formula [1]: (wherein R 1 represents a hydroxyl group or the like, m represents 0 or an integer of 1 to 5, R 2 represents a halogen atom or the like, k represents 0 or an integer of 1 to 4, R 3 , R ...
|
|
JP4796552B2 |
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
|
|
JP2011201805A |
To provide an insecticidal-acaricidal agent which exhibits a high control effect against various insect pests exhibiting resistance to conventional insecticidal-acaricidal agents, has high safety for useful organisms, and little affects ...
|
|
JP4785881B2 |
To provide an antipsychotic agent having a wider therapeutic spectrum and excellent in tolerability and safety with little adverse effects in comparison with conventional typical antipsychotics and atypical antipsychotics. A medicinal ag...
|
|
JP2011524894A |
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such comp...
|
|
JP2011524396A |
Aryl and heteroaryl ketone compounds substituted with pyrrolidines and piperidines, that modulate serotonin norepinephrine and/or dopamine neurotransmission. Also provided are pharmaceutical compositions, methods of using, and methods of...
|
|
JP4754829B2 |
The invention relates to novel carbamic acid esters of general formula (1), in which X<-> and the groups A, R<1>, R<2>, R<3> and R<4> can be defined as cited in the claims and the description. The invention also relates to a method for p...
|
|
JP2011153148A |
To provide a pharmaceutical composition for treating disorders selected from the group consisting of pain, bladder hyperactivity, urinary incontinence and inflammatory thermal hyperalgesia by inhibiting vanilloid receptor subtype 1 in ma...
|
|
JP2011148803A |
To provide compounds suitable as ligands of 5 HT receptors useful for prevention and/or treatment of various central nerval diseases.There are provided compounds represented by formula (I) (wherein, X represents CH or N; R1 represents H,...
|
|
JP4740115B2 |
The compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R3, R4 and R5 have the meanings indicated in Claim ( 1 ), are suitable as ligands of 5 HT receptors.
|
|
JP4736043B2 |
A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preve...
|
|
JPWO2009110510A1 |
Since the present invention has a neuropeptide Y receptor antagonism, it is a useful formula for the treatment of hypertension, arteriosclerosis, bulimia nervosa, obesity, etc .:[In the formula, R1Indicates a hydrogen atom, a cyano group...
|
|
JP2011132258A |
To provide a radioactive complex improved in reproducibility of initial radiochemical purity (RCP), and in stability after reconstitution.A stabilized composition comprises: (i) a metal complex of a radioactive isotope of technetium or r...
|
|
JP4714150B2 |
The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compoun...
|
|
JP4713474B2 |
The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psych...
|
|
JP4711961B2 |
This invention relates to novel (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabi
cyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates, wherein the salts are useful as monoamine neurotransmitter re...
|
|
JP4709751B2 |
A process for preparing a compound of formula (I): wherein X represents O or S; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl or C 3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl g...
|
|
JP4709752B2 |
A process for preparing a compound of formula (I): wherein X represents O or S; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl or C 3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl g...
|
